Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil

被引:20
|
作者
Dan, Y [1 ]
Murakami, H [1 ]
Koyabu, N [1 ]
Ohtani, H [1 ]
Sawada, Y [1 ]
机构
[1] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut Medicopharaceut Sci, Higashi Ku, Fukuoka 8128582, Japan
关键词
D O I
10.1211/0022357021778880
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Domperidone (DOM), a peripheral dopamine D2 receptor antagonist, is a substrate of P-glycoprotein (P-gp). Therefore, the transport of DOM into the brain may be restricted by P-gp function at the blood-brain barrier, and when the function of P-gp is impaired by ATP depletion under conditions of brain ischaemia (e.g. cerebral thrombosis), side-effects may be induced as a result of increased distribution of DOM into the brain. In this study, we investigated the effects of brain ischaemia and verapamil, a P-gp inhibitor, on the permeability coefficient-surface area product (PS values) of DOM across the blood-brain barrier by using an in-situ rat brain perfusion technique. The PS values of DOM were increased 3.4- and 3.6-fold after brain ischaemia for 10 and 20 min, respectively. Furthermore, co-administration of verapamil significantly increased the PS values of DOM by 42.6- and 43.3-fold in the normal and ischaemia groups, respectively. Brain vascular volume was not affected by ischaemia or verapamil. These results show that the transport of DOM into the brain is restricted by P-gp and that the brain distribution of DOM can be increased by cerebral ischaemia or co-administration of a P-gp inhibitor.
引用
收藏
页码:729 / 733
页数:5
相关论文
共 50 条
  • [31] Pharmacokinetics of P-Glycoprotein Inhibition in the Rat Blood-Brain Barrier
    Syvanen, Stina
    Hooker, Andrew
    Rahman, Obaidur
    Wilking, Helena
    Blomquist, Gunnar
    Langstrom, Bengt
    Bergstrom, Mats
    Hammarlund-Udenaes, Margareta
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (12) : 5386 - 5400
  • [32] Role of P-Glycoprotein in Regulating Cilnidipine Distribution to Intact and Ischemic Brain
    Yano, Kentaro
    Takimoto, Shinobu
    Motegi, Toshimitsu
    Tomono, Takumi
    Hagiwara, Mihoko
    Idota, Yoko
    Morimoto, Kaori
    Takahara, Akira
    Ogihara, Takuo
    DRUG METABOLISM AND PHARMACOKINETICS, 2014, 29 (03) : 254 - 258
  • [33] Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil
    Pirker, S.
    Baumgartner, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (12) : e151 - e151
  • [34] Use of verapamil as a potential P-glycoprotein inhibitor in patients with refractory epilepsy
    McAuley, JW
    Summers, MA
    Moore, JL
    Long, L
    Shneker, BF
    EPILEPSIA, 2004, 45 : 124 - 125
  • [35] Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy
    Summers, MA
    Moore, JL
    McAuley, JW
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (10) : 1631 - 1634
  • [36] Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter?
    Clarke, Gerard
    O'Mahony, Siobhain M.
    Cryan, John F.
    Dinan, Timothy G.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2009, 24 (03) : 217 - 223
  • [37] INTERACTION OF DRUGS WITH P-GLYCOPROTEIN IN BRAIN CAPILLARIES
    JETTE, L
    MURPHY, GF
    LECLERC, JM
    BELIVEAU, R
    BIOCHEMICAL PHARMACOLOGY, 1995, 50 (10) : 1701 - 1709
  • [38] Brain microvascular and astrocyte localization of P-glycoprotein
    Pardridge, WM
    Golden, PL
    Kang, YS
    Bickel, Y
    JOURNAL OF NEUROCHEMISTRY, 1997, 68 (03) : 1278 - 1285
  • [39] P-glycoprotein expression in hunan fetal brain
    Fattori, S.
    Colli, S.
    Castelluccio, E.
    Becherini, F.
    Nardini, V.
    Castagna, M.
    Cianfriglia, M.
    JOURNAL OF NEURAL TRANSMISSION, 2008, 115 (12) : 1733 - 1733
  • [40] Functional expression of P-glycoprotein (P-gp) in rat brain microglia.
    Lee, G
    Bendayan, M
    Bendayan, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P95 - P95